POLE and mismatch repair cancer syndrome 1: By defining four molecular subtypes and integrating key prognostic biomarkers—such as POLE mutations, mismatch repair deficiency, and p53 abnormalities—this framework enables more accurate risk stratification and precision-guided therapy.